ReviewExperimental & molecular medicine2021
Hepatocyte organoids and cell transplantation: What the future holds.
Review in Experimental & molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Mapping the knowledge domains of literature on hepatocellular carcinoma and liver failure: a bibliometric approach.Frontiers in oncology · 2025Pooled it
- A comprehensive transcriptomic comparison of hepatocyte model systems improves selection of models for experimental use.Communications biology · 2022Pooled it
- Liver organoids: From fabrication to application in liver diseases.Frontiers in physiology · 2022Pooled it
- Liver Organoids: From Disease Modelling to Regenerative Medicine.Cell proliferation · 2026Review
- An artificial intelligence optimized hepatic differentiation unveils NR5A2 and AP-1 transcriptional regulation in hepatic maturation.The Journal of biological chemistry · 2026Article
- Paracrine Factor Local Gradient-Generating System for Engineering Perfusable Vascularized Hepatocyte Tissues with Perfusion-Induced Proliferation.Advanced healthcare materials · 2026Article
- Automated and scalable expansion of human liver organoids for translational applications.Journal of translational medicine · 2026Article
- Generation of proliferative hESC-derived grape-clustered hepatocyte organoids with multipolar architecture as regenerative counterpart via synergy of YAP and IGF2 pathways.Cell death & disease · 2026Article
- Preclinical efficacy and safety evaluation of human embryonic stem cell-derived functional hepatocytes for a clinical trial in acute liver failure.Stem cell research & therapy · 2026Article
- Organoid Technology as a Promising Frontier in Organ Transplantation and Regenerative Medicine.International journal of stem cells · 2026Review
- A simple suspension culture method for generating human iPSC-derived liver organoids.Biology methods & protocols · 2026Article
- Organoid research: new concepts and new technologies.Burns & trauma · 2026Review
- Spatial patterning strategies for liver tissue engineering: Biofabrication technologies and applications.Advanced drug delivery reviews · 2026Review
- Application of stem cells in the precise diagnosis and treatment of liver diseases.World journal of gastroenterology · 2025Review
- Developments and Applications of Liver-on-a-Chip Technology-Current Status and Future Prospects.Biomedicines · 2025Review
- Article
- hESCs-derived Organoids Achieve Liver Zonation Features through LSEC Modulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- MiR-122-5p inhibits the epithelial mesenchymal transition of liver cancer cells by inducing hiPSCs to differentiate into hepatocyte-like cells.European journal of histochemistry : EJH · 2025Article
- Biomedical applications of organoids in genetic diseases.Medical review (2021) · 2025Review
- From gut to liver: organoids as platforms for next-generation toxicology assessment vehicles for xenobiotics.Stem cell research & therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Historically, primary hepatocytes have been difficult to expand or maintain in vitro. In this review, we will focus on recent advances in establishing hepatocyte organoids and their potential applications in regenerative medicine. First, we provide a background on the renewal of hepatocytes in the homeostatic as well as the injured liver. Next, we describe strategies for establishing primary hepatocyte organoids derived from either adult or fetal liver based on insights from signaling pathways regulating hepatocyte renewal in vivo. The characteristics of these organoids will be described herein. Notably, hepatocyte organoids can adopt either a proliferative or a metabolic state, depending on the culture conditions. Furthermore, the metabolic gene expression profile can be modulated based on the principles that govern liver zonation. Finally, we discuss the suitability of cell replacement therapy to treat different types of liver diseases and the current state of cell transplantation of in vitro-expanded hepatocytes in mouse models. In addition, we provide insights into how the regenerative microenvironment in the injured host liver may facilitate donor hepatocyte repopulation. In summary, transplantation of in vitro-expanded hepatocytes holds great potential for large-scale clinical application to treat liver diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.